The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look ...

New Jersey would lose about $3.6 billion a year in federal Medicaid funding, and more than 300,000 residents would risk ...

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

The company pointed to “recent market challenges” and “share price decline” as reasons for Lars Fruergaard Jørgensen’s ...